{"url_path":"/sec/bolt/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1641281/0001193125-26-344580-index.html","accession_number":"0001193125-26-344580","cik":"0001641281","ticker":"BOLT","issuer_name":"Bolt Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1641281/0001193125-26-344580-index.html","primary_entity_key":"0001641281","primary_entity_name":"Bolt Biotherapeutics, Inc."},"word_count":143,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 and a business update. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.\n\nThe information contained herein and the accompanying exhibit is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing."}